Log in with your email address username.


[Comment] Towards therapeutic choices in ulcerative colitis

Within the past few decades ulcerative colitis has become a worldwide condition, with the highest prevalence reported in developed countries and increasing incidence in developing nations.1 5-aminosalicylic acid has remained the mainstay of treatment in approximately half of patients, although several options are now available for those who become intolerant or refractory to this first-line therapy. Beyond conventional treatments such as corticosteroids and thiopurines, antitumour necrosis factor (TNFα) blockers showed efficacy more than 10 years ago in patients with refractory ulcerative colitis.